[Infection with human papillomavirus in men].
OBJECTIVE
Review updated (HPV) HPV in Man virus information, the role as a sexually transmitted infection (STI) that negatively impacts your partner(s) sexual(s) and represents a public health problem globally. In the case of men they have been identified specific risk factors that place it as the main factor in the transmission of the disease (infection, cancer and cancer precursor lesions in the genital tract), both heterosexual and homosexual practice as the subjects infected with HIV (HIV) in whom HPV prevalence rises to 95%. SEARCH METHODOLOGY: A systematic review of the literature of the past six years to date (2015) was made. Human papilloma virus vaccine, warts and sexually transmitted: In the database PubMed, LILACS and EMBASE were searched keywords. Only items that directly related to studies in men and that referred to the vaccine were analyzed.


RESULTS
The mean time of disappearance of persistent injuries HPV-6, 11, 16, and 18 (defined as two consecutive negative results) was 6.7; 3.2; 9.2; and 4.7 months respectively. In conclusion, this study showed that the acquisition of HPV-6, 11, 16, or 18 is common among men. Differences in detection rates of HPV DNA in anogenital different anatomical sites were found. It has been found that the average time of dlisappearance of lesions is ≥ 6 months. In another study conducted on a sample that included Mexican population, the median duration of HPV infection was 7.52 months (6.80-8.61) for any type of HPV and 12-19 months (7.16-18.17) for HPV-16.


CONCLUSIONS
The prevention of this disease has had a significant change with the introduction of the HPV vaccine, which has led organizations like the World Health Organization (WHO) to take a position in favor of including these biological in national immunization programs, to thereby contribute to the eradication of not only genital cancer in women, also in man, which is being reflected gradually in such programs.
Carlos Eduardo
CE
Aranda-Flores
D006801:Humans; D008297:Male; D027383:Papillomaviridae / Q000302:isolation & purification; D030361:Papillomavirus Infections / Q000453:epidemiology* / Q000517:prevention & control / Q000821:virology; D053918:Papillomavirus Vaccines / Q000008:administration & dosage*; D015995:Prevalence; D012307:Risk Factors; D012725:Sexual Behavior / Q000706:statistics & numerical data; D012749:Sexually Transmitted Diseases / Q000453:epidemiology* / Q000821:virology
D053918:Papillomavirus Vaccines